Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Extended half‐life FIX (EHL‐FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63‐year‐old patient with severe hemophilia B (sHB) treated with FIX‐Fc fusion protein (rFIXFc) who und...

Descripción completa

Detalles Bibliográficos
Autores principales: Benitez Hidalgo, Olga, Martinez Garcia, M. Fernanda, Bescos Cabestre, Agustin, Juarez Gimenez, Juan Carlos, Gironella Mesa, Mercedes, Bosch Albareda, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127245/
https://www.ncbi.nlm.nih.gov/pubmed/35620255
http://dx.doi.org/10.1002/ccr3.5848
Descripción
Sumario:Extended half‐life FIX (EHL‐FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63‐year‐old patient with severe hemophilia B (sHB) treated with FIX‐Fc fusion protein (rFIXFc) who underwent neurosurgery.

Ejemplares similares